HU9602942D0 - Taxane class derivative based pharmaceutical compositions - Google Patents

Taxane class derivative based pharmaceutical compositions

Info

Publication number
HU9602942D0
HU9602942D0 HU9602942A HU9602942A HU9602942D0 HU 9602942 D0 HU9602942 D0 HU 9602942D0 HU 9602942 A HU9602942 A HU 9602942A HU 9602942 A HU9602942 A HU 9602942A HU 9602942 D0 HU9602942 D0 HU 9602942D0
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
based pharmaceutical
derivative based
taxane class
class derivative
Prior art date
Application number
HU9602942A
Other languages
English (en)
Other versions
HUT75513A (en
HU225971B1 (en
Inventor
Manfred Durr
Joerg-Christian Hager
Armin Wendel
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of HU9602942D0 publication Critical patent/HU9602942D0/hu
Publication of HUT75513A publication Critical patent/HUT75513A/hu
Publication of HU225971B1 publication Critical patent/HU225971B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
HU9602942A 1994-04-25 1995-04-24 Taxane class derivative based pharmaceutical compositions and their preparation HU225971B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9404951A FR2718963B1 (fr) 1994-04-25 1994-04-25 Nouvelle composition pharmaceutique à base de taxoïdes.

Publications (3)

Publication Number Publication Date
HU9602942D0 true HU9602942D0 (en) 1996-12-30
HUT75513A HUT75513A (en) 1997-05-28
HU225971B1 HU225971B1 (en) 2008-01-28

Family

ID=9462475

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9602942A HU225971B1 (en) 1994-04-25 1995-04-24 Taxane class derivative based pharmaceutical compositions and their preparation

Country Status (26)

Country Link
US (1) US5670536A (hu)
EP (1) EP0758231B1 (hu)
JP (1) JP3950993B2 (hu)
KR (1) KR100401119B1 (hu)
CN (1) CN1283243C (hu)
AT (1) ATE202931T1 (hu)
AU (1) AU691283B2 (hu)
BR (1) BR9507846A (hu)
CZ (1) CZ285720B6 (hu)
DE (1) DE69521693T2 (hu)
DK (1) DK0758231T3 (hu)
ES (1) ES2160163T3 (hu)
FI (1) FI118204B (hu)
FR (1) FR2718963B1 (hu)
GE (1) GEP20002069B (hu)
GR (1) GR3036211T3 (hu)
HU (1) HU225971B1 (hu)
NO (1) NO314745B1 (hu)
NZ (1) NZ285122A (hu)
PL (1) PL179623B1 (hu)
PT (1) PT758231E (hu)
RU (1) RU2157200C2 (hu)
SK (1) SK283255B6 (hu)
TW (1) TW416849B (hu)
WO (1) WO1995028923A1 (hu)
ZA (1) ZA953358B (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
BRPI9810945B8 (pt) * 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ES2324378T3 (es) * 1998-02-05 2009-08-05 Novartis Ag Composicion farmaceutica que contiene epotilona.
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
DE10255285A1 (de) * 2002-11-26 2004-06-03 Mcs Micro Carrier Systems Gmbh Selbst formende Phospholipid-Gele
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20080262078A1 (en) * 2007-04-20 2008-10-23 Namdeo Alok B Pharmaceutical Compositions
EP1987813A1 (en) * 2007-05-04 2008-11-05 Pharmatex Italia Srl Injectable pharmaceutical formulation of taxoids in stable liposomes
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
US7895009B2 (en) * 2007-11-07 2011-02-22 Amfit, Inc. Impression foam digital scanner
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
WO2012156999A1 (en) * 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
JP5847942B2 (ja) 2012-07-19 2016-01-27 富士フイルム株式会社 タキサン系活性成分含有液体組成物、その製造方法及び液体製剤
EA022182B1 (ru) * 2012-12-24 2015-11-30 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы доцетаксела

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4507217A (en) * 1983-03-07 1985-03-26 Lipid Specialties, Inc. Magnetic compositions and magnetic memory devices prepared therefrom
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
AU3922193A (en) * 1992-03-23 1993-10-21 Georgetown University Liposome encapsulated taxol and a method of using the same
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
WO1994026253A1 (en) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation

Also Published As

Publication number Publication date
GR3036211T3 (en) 2001-10-31
SK283255B6 (sk) 2003-04-01
EP0758231B1 (fr) 2001-07-11
DK0758231T3 (da) 2001-09-24
FR2718963B1 (fr) 1996-05-24
CZ309396A3 (en) 1997-01-15
KR100401119B1 (ko) 2004-03-19
ES2160163T3 (es) 2001-11-01
SK135696A3 (en) 1997-05-07
HUT75513A (en) 1997-05-28
FR2718963A1 (fr) 1995-10-27
RU2157200C2 (ru) 2000-10-10
AU691283B2 (en) 1998-05-14
NZ285122A (en) 1998-06-26
DE69521693D1 (de) 2001-08-16
PL179623B1 (pl) 2000-10-31
JP3950993B2 (ja) 2007-08-01
EP0758231A1 (fr) 1997-02-19
NO964433D0 (no) 1996-10-18
HU225971B1 (en) 2008-01-28
WO1995028923A1 (fr) 1995-11-02
PT758231E (pt) 2001-11-30
PL316942A1 (en) 1997-02-17
ZA953358B (en) 1996-01-17
JPH09512261A (ja) 1997-12-09
BR9507846A (pt) 1997-09-16
GEP20002069B (en) 2000-05-10
CN1283243C (zh) 2006-11-08
FI964285A (fi) 1996-10-24
FI118204B (fi) 2007-08-31
NO964433L (no) 1996-10-18
FI964285A0 (fi) 1996-10-24
CN1146722A (zh) 1997-04-02
KR970702033A (ko) 1997-05-13
DE69521693T2 (de) 2002-05-02
US5670536A (en) 1997-09-23
CZ285720B6 (cs) 1999-10-13
ATE202931T1 (de) 2001-07-15
NO314745B1 (no) 2003-05-19
TW416849B (en) 2001-01-01
AU2412695A (en) 1995-11-16

Similar Documents

Publication Publication Date Title
HU9602942D0 (en) Taxane class derivative based pharmaceutical compositions
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
EP0693924A4 (en) METHODS OF ADMINISTRATION -i (IN VIVO) OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED IN SUCH METHODS
HK1024865A1 (en) Pharmaceutical compositions comprising a mixture of autocross-linked hyaluronic acid and nonautocross-linked hyaluronic acid and their use for the treatment of arthropathies
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
PT977562E (pt) Metodos e composicoes para administracao de taxanos
SE9200951D0 (sv) Pharmaceutical composition containing a defined lipid system
DK1157037T3 (da) GCSF-konjugater
PT977564E (pt) Forscolina para promocao da massa corporal magra
DE69307977T2 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
AP2002002674A0 (en) Clear Aqueous Anaesthetic composition.
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
DK0917460T3 (da) Cyclosporin-formulering
ATE241376T1 (de) Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten
ES2150404T1 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
ATE417619T1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
MX9604984A (es) Composiciones farmaceuticas a base de derivados de la clase de los taxanos.
ES2179667T3 (es) Nuevas formulaciones inyectables que contienen ramoplanina.
CA2188599A1 (fr) Compositions pharmaceutiques a base de derives de la classe des taxanes
EP0817643A4 (en) COMPOUNDS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI IRODA, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI I, HU

MM4A Lapse of definitive patent protection due to non-payment of fees